This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01578/identifier/pharmgkb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01578/identifier/pubchem-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01578/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01578/identifier/drugbank/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01578/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01578
rdf:type
n3:Drug
n3:description
Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.
n3:generalReferences
# Azuma H, Nomura S, Ikoma Y, Yokoyama M, Oshino N: A possible mechanism for the neural adverse reactions caused by metrizamide. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1989;128:134-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2568781 # Ekholm SE, Reece K, Coleman JR, Kido DK, Fischer HW: Metrizamide--a potential in vivo inhibitor of glucose metabolism. Radiology. 1983 Apr;147(1):119-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6828715
n3:group
approved
n3:indication
Metrizamide is used for lumbar, thoracic, cervical, and total columnar myelography to determine the presence of abnormalities in the spinal column, spinal canal, and central nervous system (CNS) as well as for cisternography by direct injection using standard radiologic techniques to visualize the basal cistern of the brain. For computerized tomography (CT) of the intracranial subarachnoid spaces and for ventriculography by direct injection using standard radiologic techniques to visualize the cerebral ventricles. Also used in pediatric angiocardiography to visualize lesions or malformations of the heart and obstructions or anomalies of the major thoracic vessels. Also used in adult peripheral arteriography to visualize specific regions of the vascular system and blood flow in such areas to help in the diagnosis and evaluation of neoplasms (known or suspected) or vascular diseases (congenital or acquired) that may cause changes in normal vascular anatomy or physiology. Metrizamide is also indicated in adults for intravenous digital arteriography of head and neck.
owl:sameAs
n8:DB01578 n12:DB01578
dcterms:title
Metrizamide
adms:identifier
n6:PA164742936 n9:DB01578 n10:391998 n11:443944 n13:46506223
n3:mechanismOfAction
Organic iodine compounds such as metrizamide block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of metrizamide in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, metrizamide makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs. Metrazamide also has some toxic effects which are thought to be due to its ability to inhibit glucose metabolism.
n3:synonym
Amipaque
n3:toxicity
Non-ionic radiocontrast agents like metrizamide are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
n3:IUPAC-Name
n4:271B577D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5783-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5782-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B577F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5780-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5781-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5793-363D-11E5-9242-09173F13E4C5 n4:271B577B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5795-363D-11E5-9242-09173F13E4C5 n4:271B5779-363D-11E5-9242-09173F13E4C5 n4:271B577C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B577A-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:V08AB01
n3:H-Bond-Acceptor-Count
n4:271B5789-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B578A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5784-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5785-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5787-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5786-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5788-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption from gastrointestinal tract is negligible following oral or rectal administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
31112-62-6
n3:Bioavailability
n4:271B578F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5791-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5792-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5794-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B578E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B578D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5790-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B577E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B578B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B578C-363D-11E5-9242-09173F13E4C5